Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Behaviors and Mental Disorders

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Quality of Life

All Drugs and Chemicals

Immunomodulating Agents

Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order

Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).

Participants will be randomised to receive surgery as part of multi-modality treatment

Surgery

Participants will be randomised to receive no surgery as part of multi-modality treatment

No surgery

Sally Taylor, PhD

Janelle Yorke, Prof

Seamus Grundy, MD

Matthew Evison, MD

The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2. N2 means the cancer has spread just outside the lung to the lymph nodes. There are two main treatments available in the UK for this type of lung cancer:

1. surgery PLUS chemo radiotherapy or chemotherapy
2. radiotherapy PLUS chemotherapy Patients live for a similar length of time with either treatment option so it is difficult for patients and health professionals to know which treatment to choose. It is important to understand the impact of the treatment on patients in their daily lives. Patients will be allocated at random to receive one of the two treatments options. Patients and carers will complete questionnaires and take part in interviews. The results of this study will help the investigators decide if a larger study should be conducted in the future.

The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment.The information collected will help patients and their carers in the future to make decisions about the best treatment option for them. The investigators are focusing on a particular type of lung cancer called Stage III N2. N2 means the cancer has spread just outside the lung to the lymph nodes. Around 2500 patients a year in the UK are diagnosed with this type of lung cancer. There are two main treatments available in the UK:

1. surgery PLUS chemo radiotherapy or chemotherapy
2. radiotherapy PLUS chemotherapy Patients live for a similar length of time with either treatment option so it is difficult for patients and health professionals to know which treatment to choose. Research has not explored how the two different treatments offered affect individual patients and their carer. It is important to understand the impact of the treatment on:

   * Symptoms
   * Side effects
   * Emotional well-being
   * Day to day activities

Other research studies including N2 lung cancer patients have struggled with patient recruitment. This study design will show us if it is possible to run this type of research with this group of patients. Patients will be allocated at random to receive one of the two treatments options: 1) surgery PLUS chemo radiotherapy or chemotherapy 2) radiotherapy PLUS chemotherapy Patients and carers will complete questionnaires and take part in interviews. Health professionals will also be asked to take part in interviews. These interviews will help the investigators to understand their experience of recruiting patients to this study. The results of this study will help the investigators decide if a larger study should be conducted in the future.

Impact on Quality of Life From Multi-modality Lung Cancer

ImPact on QualIty Of Life From Multi-modality Treatment for Lung caNcEr: A Randomised Controlled fEasibility tRial of Surgery Versus no Surgery as Part of Multi-modality Treatment in Potentially Resectable Stage III-N2 NSCLC (The PIONEER Trial)

Determine the proportion of patients with potentially resectable stage III N2 disease who are fit for surgery

The proportion of patients who complete their allocated treatment

Collected using the European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30)

Collected using the European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30-LC13)

Hospital Anxiety and Depression Scale (HADS)

Study specific service use and health economics questionnaire

Interviews will be conducted with patients to explore their experiences in more detail.

Carer Quality of life- cancer questionnaire

University of Manchester

The Christie NHS Foundation Trust

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery

women with stage III-IV ovarian cancer, undergoing delayed (\>5 cycles of chemotherapy) cytoreductive surgery

women with stage III-IV ovarian cancer, undergoing \>5 cycles of chemotherapy alone (no cytoreductive surgery)

cytoreductive surgery after 3-4 cycles of chemotherapy

interval cytoreductive surgery

delayed cytoreductive surgery

no cytoreductive surgery (\>5 cycles of chemotherapy alone)

no surgery

Faiza Gaba

To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.

Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following \>5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (\>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer: A GO SOAR Led Study (GO SOAR2)

defined from date of diagnosis to date of death by any cause or loss to follow-up

defined from date of diagnosis to date of first recurrence

topic guide interview questionnaire to be used to elicit factors aiding/preventing access to cytoreductive surgery internationally

R0 = no visible disease, R1 = \<10mm visible residual disease, R2 = \>10mm visible residual disease

University of Aberdeen

Barts & The London NHS Trust

Queen Mary University of London

NHS Grampian

Principle Investigator

Digestive System Diseases

Colonic Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Antineoplastic Agents

Herbal and Botanical

Dostarlimab

Cola

Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years

Saima Sharif, MD, MS

Alisha Demsky

Saima Sharif

Matt Suiter

Saima M Sharif, MD, MS

This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.

The purpose of this research study is to look at the effects of the immunotherapy drug dostarlimab on dMMR colon cancer tumors and to see if these patients can avoid surgical resection, with the option to go to surgery only if the tumor does not respond.

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers

MCR rate is defined as the proportion of patients meeting the following criteria at 18 weeks: 1) ctDNA is stable or declining, 2) a clinically asymptomatic primary tumor, and 3) no metastatic disease.

MFS is defined as the time from treatment initiation to the date of metastasis or death due to any cause, if occurring prior to surgery. Otherwise, patients will be censored at the date of surgery or last radiographic assessment, whichever occurs first.

PFS is defined as the time from treatment initiation to the date of first documentation of disease progression (defined as increasing ctDNA, symptomatic primary tumor or metastasis), or death due to any cause. Otherwise, patients will be censored at last radiographic assessment.

ORR is defined as the proportion of patients with RECIST disease response (CR, PR). All patients that do not meet the criteria for an objective response by the analysis cutoff date will be considered non-responders.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Impact on Quality of Life From Multi-modality Lung Cancer	NCT04540757	Lung Neoplasms Quality of Life	Surgery No surgery	18 Years -	The Christie NHS Foundation Trust
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers	NCT05239546	Colon Cancer dMMR Colorectal...	Dostarlimab	18 Years -	University of Iowa

Spots Global Cancer Trial Database for no surgery

Every month we try and update this database with for no surgery cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for no surgery

Every month we try and update this database with for no surgery cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for no surgery cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.